Johnson & Johnson
Change company Symbol lookup
Select an option...
JNJ Johnson & Johnson
PTI Proteostasis Therapeutics Inc
CALB California BanCorp
$NOPM2 Refinitiv Norway Metal & Mining Inde
EBAY eBay Inc
PTON Peloton Interactive Inc
GO Grocery Outlet Holding Corp
NUE Nucor Corp
SJM J M Smucker Co
KR Kroger Co
Go

Health Care : Pharmaceuticals | Large Cap Blend
Company profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Postmarket

Last Trade
Delayed
$143.91
0.04 (0.03%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$143.87
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
144.77
Day's Low
143.61
Volume
(Heavy Day)
Volume:
11,036,231

10-day average volume:
7,026,433
11,036,231

NIH confirms trial for Lilly antibody treatment is paused

7:32 am ET October 14, 2020 (MarketWatch)
Print

Shares of Eli Lilly & Co. (LLY) were down 0.5% in premarket trading on Wednesday, the day after the drug maker confirmed that a clinical trial for its COVID-19 antibody treatment in combination with remdesivir had been paused. Gilead Sciences Inc. (GILD) received emergency authorization for remdesivir in May as a COVID-19 therapeutic. The National Institutes of Health, which is sponsoring the study assessing the investigational combination treatment, on Tuesday night confirmed that enrollment in the trial had been paused, saying the data safety and monitoring board on Tuesday noticed that the study had "reached a predefined boundary for safety at day five." The trial will continue to collect data and monitor the current 326 participants who have received treatment so far. (Half of those participants received placebo, though all participants get remdesivir.) On Oct. 26, the board will recommend whether enrollment can resume. Lilly's stock is up 14.2% so far this year, while the S&P 500 has gained 8.7%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 14, 2020 07:32 ET (11:32 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.